3，Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell,1989,56:345-355.
4，Kang SM，Maeda K，Onoda N，et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer,1997，74:502-507.
5，Toi M,Hoshina S,Takayanagi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res, 1994, 85：1045-1049.
6，Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer, 1997,79：220-225.
7，Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type P53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res, 1995，55：6161-6165.
8，Kieser A, Weich HA, Brandner G, et al. Mutant P53 potentiates protein Kinase C induction of vascular endothelial growth factor expression. Oncogene, 1994, 9: 963-969.
9，杨进益，李韶.转移抑制基因nm23的研究现状（综述）.国外医学泌尿系统分册，1994，16：73-75.
10，Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin-1 complementary DNA into human breast carcinoma cell line reduces remarry tumor growth, metastatic potential, and angiogenesis. Cancer Res, 1994, 54:6504-6511.
